The clearance marks the first spine device treated with a coating that can reduce bacterial contamination in the operating room, according to a May 7 press release.
Orthobond was backed by healthcare advisory firm MCRA, which helped the company with its “pre-submission efforts in gaining FDA feedback to their proposed performance testing suite for their Ostaguard antibacterial technology,” according to the release.
MCRA’s spine team developed the regulatory strategy and supported Orthobond through the entirety of the FDA process and submitted the de novo on Orthobond’s behalf.
The FDA granted clearance to the Ostaguard antibacterial coating April 5.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
